Top Markets
#1 MowCat MowCat +48.95%
#2 Bermuda Shorts Bermuda Shorts +30.38%
#3 Velvet Velvet +24.42%
#4 Audiera Audiera +22.52%
#5 Derive Derive +21.04%
#6 aPriori aPriori +20.79%
#7 Quack AI Quack AI +19.37%
#8 Biconomy Biconomy +18.03%
#9 Perle Perle +12.23%
#10 Geodnet Geodnet +11.94%
Coin of the day
MowCat MowCat
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Aeterna Zentaris Inc. Aeterna Zentaris Inc.

Aeterna Zentaris Inc.

AEZS
Classifica tra le azioni #35469
Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company,... Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company, dedicated to the creation and market introduction of both therapeutic drugs and diagnostic tests. Its flagship product, macimorelin, is an orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist. This compound functions by binding to the GHSR-1a, thereby stimulating the secretion of growth hormone. Macimorelin is employed for diagnosing growth hormone deficiency in both adult and pediatric patients, and is also under investigation for various oncology indications. The drug is marketed commercially under the brand name Macrilen. The company engages in various licensing agreements, prominently with University Wuerzburg. This collaboration encompasses the research, development, manufacture, and commercialization of a prospective COVID-19 vaccine. It also involves developing, producing, and marketing a treatment for neuromyelitis optica spectrum disorder (NMOSD), establishing human 3D intestinal tissue models for infection biology research, and advancing pre-clinical work towards a potential Parkinson's disease therapy. Additionally, Aeterna Zentaris has formed licensing partnerships with Consilient Health Ltd., Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada. Another key collaboration is with The University of Sheffield in the United Kingdom, dedicated to the research, development, manufacturing, and commercialization of parathyroid hormone fusion polypeptides designed to treat primary hypoparathyroidism. Founded in 1990, Aeterna Zentaris Inc. maintains its corporate headquarters in Summerville, South Carolina.
Prezzo delle azioni
$3.97
Ultima sincronizzazione: 2024-09-03
Capitalizzazione di mercato
$3.86M
Variazione (1 giorno)
-1.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Aeterna Zentaris Inc. (AEZS)

Categoria

Healthcare
Cronologia dei frazionamenti azionari per Aeterna Zentaris Inc. (AEZS)
L’azione Aeterna Zentaris Inc. (simbolo: AEZS) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Aug 16, 2026.
Una quota di AEZS acquistata prima di Aug 16, 2026 equivale oggi a 0 quote di AEZS.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 0 -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0 -
BE